Phaseline

Targets › GP120

GP120: drug programs, companies and trials

2 programs from 2 companies in 7 trials: 3 Phase 1, 2 Phase 3, 1 Phase 4, 1 Phase 2; Infectious disease; next expected readout Jan 2027.

Open in Phaseline: the race on GP120, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKFostemsavir
Envelope polyprotein GP160 inhibitor
INSTI, GP120, CD4Phase 3HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant VirusJan 2027
Steven DeeksLVgp120duoCAR-T cells
CAR-T cells expressing dual CAR targeting gp120, the envelope glycoprotein of HIV
GP120, ENVPhase 1HIV InfectionsDec 2028

Conditions

HIV Infections (4) HIV-1-infection (1) Human Immunodeficiency Virus (HIV) (1) HIV Infections With Multi Drug Resistant Virus (1)

Modalities

mixed (2)

Companies

GSK (1) Steven Deeks (1)

Related targets

INSTI (1) CD4 (1) ENV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.